Merck commitment

Merck’s commitment to HIV

Merck’s commitment to HIV: 30 years and counting

Contributing to the fight against HIV since 1985

ISENTRESS® and ISENTRESS HD® (raltegravir) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.

Consult the Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-567-2594.

* No longer available in Canada.

NNRTI=non-nucleoside reverse transcriptase inhibitor; MRL=Merck Research Labs; ART=antiretroviral therapy

CA-DOR-00155